Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monte Rosa TherapeuticsGLUE -4.52%34 Pretax Margin % is -1,055.84% as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Monte Rosa Therapeutics ranks worse than 64.93% on this metric.
The historical rank and industry rank for Monte Rosa Therapeutics's Pretax Margin % or its related term are showing as below:
GLUE'
s Pretax Margin % Range Over the Past 10 Years
Min: -307.04 Med: -62.43 Max: -32.12
Current: -307.04
GLUE's Pretax Margin % is ranked worse than 64.93% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs GLUE: -307.04
Monte Rosa Therapeutics (NAS:GLUE) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Monte Rosa Therapeutics Pretax Margin % Related Terms
Monte Rosa Therapeutics Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLUE vs SNDX, IOVA, TYRA: Pretax Margin % Comparison
For the Biotechnology subindustry, Monte Rosa Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monte Rosa Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Monte Rosa Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics (GLUE) has a Pretax Margin % of -1,055.84% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Monte Rosa Therapeutics and its competitors. According to the industry distribution chart, Monte Rosa Therapeutics ranks #611 out of 941 companies in the Biotechnology industry, placing it in the top 64.9%.
Is Monte Rosa Therapeutics' Pretax Margin % too high?
Monte Rosa Therapeutics' current Pretax Margin % is -1,055.84%. Based on the distribution chart, Monte Rosa Therapeutics ranks #611 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Pretax Margin % compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #611 out of 941 companies for Pretax Margin %. This places Monte Rosa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current Pretax Margin % is -1,055.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Pretax Margin % of -1,055.84%. The current Pretax Margin % is -1,055.84%. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Pretax Margin % is -1,055.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score
Get the complete analysis for GLUE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLUE has been successfully added to your 
